Successful phase 2a clinical study reinforces novel approach to treat Multiple Sclerosis GeNeuro SA announced today positive results from a one-year, open-label extension of a Phase IIa study. GeNeuro tested its monoclonal antibody GNbAC1 in 10 multiple sclerosis (MS) patients, nine of which had primary or secondary progressive disease. GNbAC1 targets the MSRV-Env protein expressed by genes of endogenous retroviral origin, which GeNeuro believe plays a critical role in the pathogenesis of MS..... Read More - ms-uk.org/emergingtherapies
Posted on: Thu, 04 Sep 2014 08:44:34 +0000